Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Stephen K Chia"'
Publikováno v:
Current Oncology, Vol 30, Iss 8, Pp 7263-7274 (2023)
Recent exciting advances in the diagnosis and management of breast cancer have improved outcomes for Canadians diagnosed and living with breast cancer. However, the reach of this progress has been uneven; disparities in accessing care across Canada a
Externí odkaz:
https://doaj.org/article/e43dc4f3d58649a7b6a2974dabb620be
Autor:
Stephen K. Chia, David W. Cescon, Andrew D. Redfern, Danielle Rodin, Christine Simmons, Jean-Pierre Ayoub, Haji Ibrahim Chalchal, Daniel Rayson, Moira Rushton-Marovac, Tracey Hay, Lisa Gallinaro, Bingshu Chen, Wendy Parulekar
Publikováno v:
Cancer Research. 83:OT3-26
Background: The PI3K/AKT/mTOR pathway is a rational target in the metastatic disease setting for hormone receptor positive breast cancer based on preclinical and clinical data demonstrating that pathway inhibition improves outcome (Baselga 2012, Andr
Autor:
Hope Rugo, Stephen K. Chia, Javier Cortés, Giuseppe Curigliano, Patrick Neven, Rebecca Dent, Sara Tolaney, Eva Ciruelos, Yeon H. Park, Estelle Roux, Yogesh Chattar, Heather Patino, Murat Akdere, Dejan Juric
Publikováno v:
Cancer Research. 83:PD13-06
Introduction: PIK3CA mutations, seen in ~40% of patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC), are associated with treatment (Tx) resistance and shorter s
Autor:
Dejan Juric, Nicholas Turner, Sherene Loi, Fabrice Andre, Stephen K. Chia, Komal Jhaveri, Patrick Neven, Rebecca Dent, Eva Ciruelos, Mukta Joshi, Estelle Roux, Heather Patino, Murat Akdere, Hope Rugo
Publikováno v:
Cancer Research. 83:P4-09
Introduction: Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) is mutated in ~40% of patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cance
Autor:
Charles E. Geyer, Jr, Gong Tang, Priya Rastogi, Vicente Valero, Stephen K. Chia, Erin F. Cobain, Elias Obeid, David B. Page, Andrew S. Poklepovic, William J. Irvin, Jr., Adam M. Brufsky, Irene L. Wapnir, Jennifer M. Suga, Eleftherios (Terry) Mamounas, Norman Wolmark
Publikováno v:
Cancer Research. 83:OT2-16
Background: The CLEOPATRA trial established trastuzumab, pertuzumab and a taxane (THP) as a standard of care for first line metastatic, HER2-positve breast cancer with median progression-free survival (PFS) of 18.7 months and median OS of 57 months.
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-13 (2018)
Abstract Background Adjuvant endocrine therapy (AET) significantly decreases the risk of breast cancer recurrence and mortality. Notwithstanding the demonstrated efficacy of AET, 31–73% of breast cancer survivors do not persist with AET. The purpos
Externí odkaz:
https://doaj.org/article/3ec720909f6b4668b056221973a06f92
Autor:
Eleftherios P Mamounas, Hanna Bandos, Priya Rastogi, Barry C Lembersky, Jong-Hyeon Jeong, Charles E Geyer, Louis Fehrenbacher, Stephen K Chia, Adam M Brufsky, Janice M Walshe, Gamini S Soori, Shaker R Dakhil, James L Wade, Edward C McCarron, Sandra M Swain, Norman Wolmark
Publikováno v:
JNCI: Journal of the National Cancer Institute.
Background NSABP B-42 evaluated extended letrozole therapy (ELT) in postmenopausal breast cancer patients who were disease-free after 5 years of aromatase inhibitor-based (AI) therapy. Seven-year results demonstrated a non-statistically significant t
Autor:
Stephen K. Chia, Susan L. Ellard, Mihaela Mates, Stephen Welch, Catalin Mihalcioiu, Wilson H. Miller, Karen Gelmon, Caroline Lohrisch, Vikaash Kumar, Sara Taylor, Linda Hagerman, Rachel Goodwin, Tao Wang, Shingo Sakashita, Ming S. Tsao, Elizabeth Eisenhauer, Penelope Bradbury
Publikováno v:
Breast Cancer Research, Vol 19, Iss 1, Pp 1-8 (2017)
Abstract Background The mechanisms of resistance to anti-human epidermal growth factor receptor 2 (HER 2) therapies are unclear but may include the tyrosine-protein kinase Met (c-Met), vascular endothelial growth factor (VEGF) and AXL pathways. Foret
Externí odkaz:
https://doaj.org/article/339a000fc2ce4f629f2c9ae8021f9690
Publikováno v:
OncoImmunology, Vol 7, Iss 11 (2018)
Tumor-infiltrating lymphocytes (TILs) are predominantly present in breast cancer patients with estrogen receptor negative tumors, among whom increasing levels correlate with favorable outcomes. Nevertheless, currently available immune checkpoint inhi
Externí odkaz:
https://doaj.org/article/481d4dc6ccd6426893337d8f7ddf19da
Autor:
Torsten O. Nielsen, Charles M. Perou, Philip S. Bernard, Matthew J. Ellis, Joel S. Parker, Mark T.W. Ebbert, Carole Davis, Inge J. Stijleman, Sherri Davies, Kathleen I. Pritchard, Mark N. Levine, Lois E. Shepherd, Stephen K. Chia, Samuel Leung, Shan Jiang, Dongsheng Tu, K. David Voduc, Maggie C.U. Cheang
PDF file - 44K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0bdef29a39de8ebccd33401bfe5e6092
https://doi.org/10.1158/1078-0432.22443840
https://doi.org/10.1158/1078-0432.22443840